Aeolus Pharmaceuticals' Unattributed - II Round

Aeolus Pharmaceuticals raised a round of funding on December 18, 2015.

Aeolus is developing a variety of therapeutic agents based on its proprietary small molecule catalytic antioxidants, with AEOL 10150 being the first to enter human clinical evaluation. AEOL 10150 is a…

Articles about Aeolus Pharmaceuticals' Unattributed - II Round: